CT 2074
Alternative Names: CT-2074Latest Information Update: 11 Feb 2022
At a glance
- Originator Cognition Therapeutics
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Sigma-2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 19 Jul 2021 Cognition Therapeutics has patents pending for CT 2074 in the US prior to July 2021
- 19 Jul 2021 Cognition Therapeutics has patents pending for CT 2074 in the numerous foreign jurisdictions prior to July 2021
- 19 Jul 2021 Preclinical trials in Dry age-related macular degeneration in USA (PO) prior to July 2021 (Cognition Therapeutics, February 2022)